Action 460 SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Sihuan Pharmaceutical Holdings Group Ltd. Shanghai - Hong Kong Stock Connect

Actions

460

BMG8162K1137

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Sihuan Pharma Unit's Microvascular Disease Drug Gets China Registration Approval
Chinese Regulator Approves Drug Registration for Sihuan Pharmaceutical's Subsidiary's Ticagrelor Orodispersible
Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration
Sihuan Pharmaceutical Holdings Group Ltd. commences an Equity Buyback Plan for 932,999,920 shares, representing 10% of its issued share capital, under the authorization approved on June 7, 2024.
Sihuan Pharmaceutical Unit Gets Nod for Weight-Loss Drug Application in China
Sihuan Pharma Subsidiary Licenses Fadanafil Drug to Livzon Pharmaceutical Unit
Xuanzhu Biopharmaceutical Co., Ltd. and Livzon Group Livzon Pharmaceutical Factory Reaches an Exclusive Licensing Cooperation on Fadanafil
Chinese Regulators Approve Sihuan Pharmaceutical’s Drug Registration Application
Sihuan Pharmaceutical Holdings Group Ltd. Announces Rivaroxaban Tablets (Strength: 2.5Mg) Obtained Drug Registration Approval from NMPA
Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China
Sihuan Pharmaceutical, Unit Withdraw Latter's Stock Exchange Bid, Shares Down by Over 3%
Sihuan Pharmaceutical Unit's Lung Cancer Drug NDA Accepted by NMPA, Stocks Shoot Over 10%
Sihuan Pharma Unit Wins Bid to Supply Insulin Products to Chinese Government
Sihuan Pharmaceutical Narrows 2023 Loss on Absence of Asset, Investment Impairments
Sihuan Pharmaceutical Holdings Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Sihuan Pharmaceutical's RF Device Wins Registration Approval in China
Sihuan Pharmaceutical Holdings Unit Forms Consortium for Ji Yao Restructuring
China Approves Drug Registration for Sihuan Pharmaceutical Unit's Type 2 Diabetes Drug
Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 460
  4. Action 460
  5. Actualités Sihuan Pharmaceutical Holdings Group Ltd.
  6. Autres langues